Drug intelligence / Profile preview

EcNΔlpp::A5

Development stage: Preclinical
Lead developer: China Pharmaceutical University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

EcNΔlpp::A5 is an engineered live probiotic based on **Escherichia coli Nissle 1917 (EcN)**. It is genetically modified to display **Annexin A5 (ANXA5)** on its surface, enhancing its targeting and colonization at sites of intestinal inflammation where phosphatidylserine (PS) is exposed on apoptotic colon epithelial cells. Additionally, the lipoprotein gene (**lpp**) is knocked out to increase secretion capability. EcNΔlpp::A5 acts by improved localization to inflamed mucosa and modulation of mucosal immune responses, showing efficacy in alleviating ulcerative colitis in preclinical models[2]. The strain forms the basis for subsequent therapeutic constructs (e.g., EcNΔlpp::A5-aTN, which further secretes anti-TNF-α nanobodies), but EcNΔlpp::A5 itself does not secrete anti-TNF agents[2]. Developed for **targeted drug delivery** and **microbiome therapy** primarily for **ulcerative colitis** and other inflammatory bowel diseases.

Brand names: EcNΔlpp::A5
Other names: EcNΔlpp::A5

Targets

PS (Phosphatidylserine)

Beyond the preview

Go deeper on EcNΔlpp::A5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EcNΔlpp::A5.

Explore the full profile